Bio-Gene Technology Limited (ASX:BGT)

Bio-Gene Technology Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Revenue	-	-	0.02	0.15	0.45	0.06
Revenue Growth (YoY)	-	-	-87.72%	-66.52%	611.91%	-49.01%
Cost of Revenue	-0.08	0.25	0.32	0.27	0.22	0.12
Gross Profit	0.08	-0.25	-0.3	-0.12	0.22	-0.06
Selling, General & Admin	1.54	1.44	1.69	1.48	1.23	0.87
Research & Development	1.93	1.38	1.07	1.98	1.9	1.68
Other Operating Expenses	-0.9	-0.48	-0.6	-0.45	0.02	-0.22
Operating Expenses	2.62	2.38	2.19	3.06	3.19	2.38
Operating Income	-2.54	-2.62	-2.5	-3.18	-2.97	-2.43
Interest Expense	-	-	-	-	-	-0
Interest & Investment Income	0.02	0.04	0.09	0.09	0.05	0.04
Other Non Operating Income (Expenses)	0	0	-0	-	-	-
EBT Excluding Unusual Items	-2.52	-2.58	-2.41	-3.1	-2.91	-2.4
Pretax Income	-2.52	-2.58	-2.41	-3.1	-2.91	-2.4
Net Income	-2.52	-2.58	-2.41	-3.1	-2.91	-2.4
Net Income to Common	-2.52	-2.58	-2.41	-3.1	-2.91	-2.4
Shares Outstanding (Basic)	263	211	186	168	153	137
Shares Outstanding (Diluted)	263	211	186	168	153	137
Shares Change (YoY)	34.05%	13.68%	10.76%	9.41%	11.73%	14.96%
EPS (Basic)	-0.01	-0.01	-0.01	-0.02	-0.02	-0.02
EPS (Diluted)	-0.01	-0.01	-0.01	-0.02	-0.02	-0.02
Free Cash Flow	-2.62	-2.54	-2.76	-3.28	-2	-1.83
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.02	-0.01	-0.01
Gross Margin	-	-	-	-79.57%	49.83%	-90.03%
Operating Margin	-	-	-13625.67%	-2132.08%	-665.67%	-3887.62%
Profit Margin	-	-	-13150.54%	-2074.48%	-653.81%	-3827.29%
Free Cash Flow Margin	-	-	-15065.19%	-2195.48%	-448.66%	-2920.54%
EBITDA	-2.49	-2.58	-2.46	-3.14	-2.92	-2.39
D&A For EBITDA	0.04	0.04	0.04	0.05	0.04	0.04
EBIT	-2.54	-2.62	-2.5	-3.18	-2.97	-2.43
Revenue as Reported	0.52	0.52	0.71	0.68	0.94	0.64

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.